Literature DB >> 34823729

Perioperative Buprenorphine Management: A Multidisciplinary Approach.

Thomas Hickey1, Audrey Abelleira2, Gregory Acampora3, William C Becker4, Caroline G Falker2, Mitchell Nazario5, Melissa B Weimer6.   

Abstract

Buprenorphine formulations (including buprenorphine/naloxone) are effective treatments of pain and opioid use disorder (OUD). Historically, perioperative management of patients prescribed buprenorphine involved abstinence from buprenorphine sufficient to allow for unrestricted mu-opioid receptor availability to full agonist opioid (FAO) treatment. Evidence is mounting that a multimodal analgesic strategy, including simultaneous administration of buprenorphine and FAO, nonopioid adjuncts such as acetaminophen and nonsteroidal anti-inflammatory drugs, and regional anesthesia, is a safe and effective perioperative strategy for the patient prescribed long-term buprenorphine treatment of OUD. This strategy will likely simplify management and more seamlessly provide continuous buprenorphine treatment of OUD after hospital discharge.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analgesia; Buprenorphine; Opioid-related disorders; Pain; Partial opioid agonists; Postoperative

Mesh:

Substances:

Year:  2022        PMID: 34823729     DOI: 10.1016/j.mcna.2021.09.001

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  2 in total

Review 1.  Perioperative and Periprocedural anesthetic management of opioid tolerant patients and patients with active and medically treated opioid use disorder.

Authors:  Stacey L Burns; Petra Majdak; Richard D Urman
Journal:  Curr Opin Anaesthesiol       Date:  2022-07-05       Impact factor: 2.733

2.  Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.

Authors:  Susan L Calcaterra; Marlene Martin; Richard Bottner; Honora Englander; Zoe Weinstein; Melissa B Weimer; Eugene Lambert; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.